Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605808 | 0.86 | MAPT (0.43) | AAK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4628583 | 0.86 | CES2 (0.41) | AAK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3842336 | 0.84 | L3MBTL1 (0.41) | FLT1FLT4KDRGABRA1GABRG2 | |
| SCHEMBL1184775 | 0.83 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12301378 | 0.82 | KMT2A (0.44) | RAB9ANPC1SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL1315426 | 0.81 | MAPT (0.44) | AAK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL643318 | 0.81 | DGAT1 (0.54) | AAK1FLT1FLT4KDRUSP30 | |
| SCHEMBL19900085 | 0.81 | SMN1; SMN2 (0.40) | AAK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4628585 | 0.81 | KDM4E (0.47) | — | |
| SCHEMBL15920614 | 0.81 | KDM4E (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250084056-A1 | SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-13 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-115073474-B | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118451078-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | LUDWIG-MAXIMILIANS-UNIVERSITAT MUENCHEN (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009080250-A2 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080250-A2 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084056-A1 | SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS | CCNA1, CCNI, CCNE1 | AAK1 2111/4885UTS2R 1547/4885FLT1 848/4885 |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | AAK1 945/4885UTS2R 121/4885FLT1 957/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | AAK1 945/4885UTS2R 121/4885FLT1 957/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | AAK1 79/4885UTS2R 2267/4885FLT1 3234/4885 |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | AAK1 3857/4885UTS2R 794/4885FLT1 1752/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | AAK1 3571/4885UTS2R 3363/4885FLT1 3485/4885 |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | MLX, GLRX3, SFXN3 | AAK1 4632/4885UTS2R 2606/4885FLT1 4155/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | AAK1 1512/4885UTS2R 3609/4885FLT1 3029/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | AAK1 2094/4885UTS2R 2383/4885FLT1 249/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | AAK1 3571/4885UTS2R 3363/4885FLT1 3485/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | AAK1 945/4885UTS2R 121/4885FLT1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.